TRAVERE THERAPEUTICS INC (TVTX)
NASDAQ • Healthcare
Last close at August 11, 2026 at 20:00 UTC
Fundamentals Charts
About TRAVERE THERAPEUTICS INC
Travere Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing and commercializing therapies for rare kidney and metabolic diseases, with $490.7 million in revenue in FY2025. Its business centers on specialty medicines for small patient populations, led by FILSPARI for rare kidney disorders and Thiola-based treatments for cystinuria.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
TRAVERE THERAPEUTICS INC's Technical Indicators Summary
TVTX exhibits a strong bullish alignment as price is trading above short- and long-term moving averages and momentum measures, including a positive MACD and solid RSI, support upward bias. ADX near 25 indicates a developing trend, while ATR shows moderate volatility and short-term bands are orderly. Notably, intraday VWAP and on-balance-volume diverge, suggesting price strength is not yet fully confirmed by volume. Overall strength across moving averages and momentum underpins the stance. Technical takeaway: Strong Buy.
| Indicator | Value |
|---|---|
RSI (14) | 62.72 |
Stochastic %K (14, 3, 3) | 58.27 |
CCI (20) | 95.54 |
WPR (14) | -36.42 |
Momentum (10) | 6.01 |
MFI | 57.00 |
MACD Level (12, 26) | 1.66 |
Bollinger Bands | $52.53 - $63.05 |
ATR (14) | $2.82 (4.59%) |
ADX (14) | 24.95 |
OBV | 11,684,400 |
VWAP | $61.75 |
Classic Pivot Point | $60.79 |
Fibonacci Pivot Point | $60.79 |
Simple Moving Averages | $39.67 - $59.34(5 indicators) |
Exponential Moving Averages | $41.15 - $59.78(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
TVTX advances 2.62% above yesterday’s close of 60.21. Sector performance is neutral (0.25%), offering little directional push for TVTX. TVTX's FILSPARI saw 96% YoY net sales growth amid robust FSGS launch demand.
Trading Volume
Below 10d avg (2.1M)
347.6K
vs S&P 500 Today
Outperforming Market
+2.37%
52-Week Position
Near highs
91%
Updated: August 12, 2026 at 16:41 UTC